Replimune beats, details rapid early U.S. TUDRIQEV launch uptake and broad payer coverage
Replimune beats fiscal Q2 2027 estimates, details rapid early U.S. TUDRIQEV launch uptake and broad payer coverage
- Fiscal Q2 2027 non-GAAP EPS was $-0.54 (+40% YoY) on revenue of $0 (-100% YoY).
- Quarterly loss beat expectations and narrowed versus the prior-year period, helped by lower R&D and SG&A expenses.
- Approximately 20 U.S. institutions have already adopted TUDRIQEV in the early launch phase.
- Company highlighted broad payer coverage for TUDRIQEV, supported by an NCCN Category 2A listing.
- Management cited high engagement across priority accounts in the early phase of the TUDRIQEV launch.
- Replimune ended the quarter with $307.8 million in cash, providing more than 12 months of runway.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.